KY1049 / Sanofi - LARVOL DELTA

A FULLY Human Bispecific Antibody Functionally Rescues Factor VIII Deficiency EX VIVO (ASH 2019) - "KY1049, developed using Kymab’s IntelliSelect® Bispecific platform, is a potent F.VIII mimetic bispecific antibody with activities comparable to a SIA of Hemlibra®. This fully human CLC bispecific antibody can potentially provide a new treatment option for hemophilia A patients."

Preclinical • F2

Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition (GlobeNewswire, Kymab Group Ltd) - "Kymab...today announced that abstracts describing two lead hematology programs, KY1049 and KY1066, will be presented at the American Society of Hematology 61st Annual Meeting and Exposition, being held December 7-10, 2019 in Orlando, Florida. The presentations will include posters highlighting preclinical data from these portfolio programs: KY1049 (a fully-human FVIII-mimetic common light chain bispecific antibody) and KY1066 (a fully-human antibody against matripase-2 for the treatment of iron overload in anemia)."

Preclinical

DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A (EHA 2019) - "Further optimisation of the molecule was carried out to iteratively increase FVIII mimetic activity by deep data-mining of heavy chain NGS sequence data, or site-specific mutagenesis. The combinatorial optimization process resulted in a highly functional CLC bispecific, KY1049 with comparable F.VIII mimetic activities to a sequence-identical analogue of Hemlibra (Figure 1C).Conclusion Our bispecific antibody discovery platform consisting of four-chain matrix screening, common light chain transgenic mouse technology, B cell network analysis and site-specific mutagenesis was applied to develop KY1049, a potent FV.III mimetic bispecific antibody, which shows equivalent activity to Hemlibra in vitro and holds promise as a future therapeutic in Haemophilia A."

Clinical

A FULLY HUMAN BISPECIFIC ANTIBODY FUNCTIONALLY RESCUES FACTOR VIII DEFICIENCY EX VIVO (EHA 2019) - "Its therapeutic benefit is likely to be at least as effective as Hemlibra. Furthermore, initial analysis of the KY1049 molecule also showed some differences between the two molecules which could be harnessed to enhance its physical properties and activity."

Preclinical

"Preclinical data for KY1049 presented at EHA2019, Amsterdam #bispecific #antibody #EHA24 #EHA2019" (@bio_jkb)

Preclinical

Kymab Announces Presentations at the 24th EHA Annual Congress (GlobeNewswire, Kymab Group Ltd) - "Kymab...today announced that two abstracts describing KY1049, Kymab’s fully-human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the 24th European Hematology Association Annual Congress in Amsterdam, being held June 13-16....'We are pleased to present at this prestigious meeting some very exciting preclinical data on KY1049, the first naturally-evolved fully-human bispecific antibody generated by our proprietary IntelliSelect Bispecifics platform.'"

Preclinical